Biontech stock.

A Look at BioNTech SE's Growth Numbers. Over the last three years, BioNTech SE has shrunk its earnings per share by 54% per year. In the last year, its …Business Summary. BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which …Investors & Media. Welcome to our investor page. Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the ...BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, November 6, 2023, at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter of 2023. To access the live conference call via telephone, please register via this link.

BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock rally from about $80 at the end of 2020 to levels of almost $420 currently, marking an ...

MAINZ, Germany, January 6, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) today announced that the Company signed a Memorandum of Understanding (“MoU”) with the Government of the United Kingdom (“UK”) to benefit patients by accelerating clinical trials for personalized mRNA immunotherapies with the …Dec 28, 2023 · BioNTech, like all Covid-19 vaccine makers, has gotten crunched in 2023. But it has so much cash that it would have appealed to Warren Buffett’s mentor, famed value manager Benjamin Graham.

As of May 2024 BioNTech has a market cap of $21.90 Billion . This makes BioNTech the world's 865th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company …BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by about 2% over the last week (five trading days) and also remains down by about ...Apr 12, 2024 · Discover real-time BioNTech SE American Depositary Share (BNTX) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq. Their BNTX share price targets range from $90.00 to $171.00. On average, they expect the company's stock price to reach $117.25 in the next year. This suggests ...

MAINZ, GERMANY, October 1, 2021 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial. The trial has been initiated in the …

Shares traded 424.39k. 1 Year change -19.68% Beta 0.2477. Data delayed at least 15 minutes, as of May 01 2024 21:00 BST. Find More Stocks. Use our equities screener to …

Meanwhile, BioNtech is not the only vaccine maker Bill Gates has invested in. As Fool.com also wrote, Microsoft co-founder through his Bill & Melinda Gates Foundation, also invested in three other coronavirus vaccine stocks Pfizer, CureVac, and Vir Biotechnology. Per Fool.com, in 2015, his foundation invested $52 million in CureVac.BioNTech stock (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 ...Complete BioNTech SE ADR stock information by Barron's. View real-time BNTX stock price and news, along with industry-best analysis.BioNTech SE - ADR (22UA) Stock Price & News - Google Finance. Home 22UA • FRA. BioNTech SE - ADR. €83.05. Apr 30, 11:00:14 PM GMT+2 · EUR · FRA · Disclaimer. …BioNTech’s announcement came after Pfizer cut its guidance for the Covid vaccine, ... The stock fell another 3 per cent to $31.13 in US pre-market trading on Monday.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.However, the good news is that BioNTech has plenty of cash on hand. As of June 30, the company's cash and cash equivalents came in at 14.2 billion euros ($15.1 billion), compared with 13.9 billion ...Biontech Se Biontech Se Adr is listed on the London Stock Exchange trading with ticker code 0A3M.L. It has a market capitalisation of $21.91b, with approximately 240.99m shares in issue. Over the ...Moderna stock and BioNTech led a sell-off Monday among Covid vaccine makers after Pfizer slashed about $9 billion from its full-year guidance.. X. Pfizer said it wrote off about $5.5 billion in ...Get the latest price, performance, and news for BioNTech SE ADR (BNTX), a German biotech company developing immunotherapies for cancer and other diseases. …Analysts have set 12-month price targets for BioNTech, revealing an average target of $145.43, a high estimate of $171.00, and a low estimate of $100.00. This upward trend is evident, with the ...

Complete BioNTech SE ADR stock information by Barron's. View real-time BNTX stock price and news, along with industry-best analysis. BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript. BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript May 6, 2024 BioNTech SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to BioNTech’s First Quarter 2024 Earnings Call.

Aug 7, 2023 · BNTX stock analysts projected a per-share loss of 30 cents. BioNTech blamed write-offs to partner Pfizer for the profit and sales hits. On today's stock market, BNTX stock toppled 7.5% to 98.50 ... BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the ... The latest BioNTech stock prices, stock quotes, news, and BNTX history to help you invest and trade smarter. BioNTech stock rose 0.7% over a five day trading period ending 10/15/2021, compared to the broader market (S&P500) which rose by 1.8%; A change of 0.7% or more over five trading days has a 56% ... The latest BioNTech stock prices, stock quotes, news, and BNTX history to help you invest and trade smarter. Mar 28, 2024 ... In 2023, the number of shares of biotech company BioNTech SE was around 243 million compared to around 250 million shares in the previous ...Stock Price Statistics The stock price has decreased by -14.48% in the last 52 weeks. The beta is 0.26, so BioNTech SE's price volatility has been lower than the market average.Complete BioNTech SE ADR stock information by Barron's. View real-time BNTX stock price and news, along with industry-best analysis.2:08p Dell’s stock is having a milestone day. Here’s why Morgan Stanley is so bullish. ... BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious ...MAINZ, GERMANY, October 1, 2021 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial. The trial has been initiated in the …

BioNTech's stock has underperformed the broader market as it is off 27% in the last year compared to the SP500 being up 32%. StockCharts.com. Per Fintel, BioNTech's short interest makes up 3.38% ...

BioNTech to pay an upfront consideration of approximately £362 million in cash and BioNTech shares, to acquire 100% of remaining InstaDeep shares following BioNTech’s Series B investment in 2022

A major windfall. Based in Germany, BioNTech was originally founded in 2008 and made its debut on the stock market in the U.S. in late 2019. It was a relatively unknown company then, but its ...80.90%. -16.75%. -163.26%. -35.78%. -95.66%. Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC). Detailed annual and quarterly income statement for BioNTech SE (BNTX). See many years of revenue, expenses and profits or losses.BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the ...BNTX. -0.47%. On Monday, Evercore ISI began coverage on shares of BioNTech (NASDAQ: BNTX ), assigning an "In Line" rating and setting a price target of $100. The firm's analysis pointed to the ...Over Q1 2021, BioNTech posted revenue of about $2.5 billion, with Net Margins coming in at a solid 55%. However, despite the strong financials, BioNTech stock trades at just 6x projected 2021 ...The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities. BioNTech SE ...Feb 20, 2024 · Insights from analysts' 12-month price targets are revealed, presenting an average target of $127.5, a high estimate of $171.00, and a low estimate of $99.00. This current average has decreased by ... Aug 18, 2023 · Moderna and BioNTech are no longer minting money from Covid vaccines. But both have strong drug pipelines and plenty of cash. A major windfall. Based in Germany, BioNTech was originally founded in 2008 and made its debut on the stock market in the U.S. in late 2019. It was a relatively unknown company then, but its ...Particularly in BioNTech's oncology pipeline, there will soon be enough mid-stage clinical projects approaching critical readouts to make predicting the stock's price an exercise in futility.Sep 29, 2021 ... BioNTech, a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the ...Feb 27, 2023 · BioNTech SE Sponsored ADR (BNTX) closed at $130.86 in the latest trading session, marking a -1.84% move from the prior day. This change lagged the S&P 500's daily gain of 0.31%.

BioNTech to pay an upfront consideration of approximately £362 million in cash and BioNTech shares, to acquire 100% of remaining InstaDeep shares following BioNTech’s Series B investment in 2022We at BioNTech believe that the immune system is the fundamental driver for therapeutic success in cancer, and infectious diseases and other serious diseases. As immune engineers we have a deep understanding of the underlying mechanisms that enable the immune system to effectively recognize both external threats like infectious diseases and … BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript. Find the latest BioNTech SE (BNTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Instagram:https://instagram. best buy electronic recyclingcandy crush crush sagayoutube affiliate marketingmsp to dublin The average 12-month price target for BioNTech stock right now is $261.95, roughly 25% lower than the current share price. That average is based on Refinitiv's survey of 12 analysts. mozilla browser apkpa driver's exam BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, May 8, 2023 at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial ...However, the good news is that BioNTech has plenty of cash on hand. As of June 30, the company's cash and cash equivalents came in at 14.2 billion euros ($15.1 billion), compared with 13.9 billion ... houston parking BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock rally from about $80 at the end of 2020 to levels of almost $420 currently, marking an ...BioNTech stock tumbled to its lowest point in three years Wednesday after the Covid vaccine maker reported light fourth-quarter sales and profit, and delivered lackluster 2024 guidance.. X. The ...